Vancouver, WA – According to filings with the U.S. Securities and Exchange Commission, CytoDyn is raising $25,220,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Antonio Migliarese played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CytoDyn
CytoDyn is a late-stage biotech company advancing targeted therapies to address cancer, HIV and other autoimmune diseases, with the goal of improving the quality of life for patients and simplifying treatment plans. In oncology, CytoDyn is conducting a Phase 1b/2 clinical trial to evaluate its targeted therapy for the treatment of metastatic triple-negative breast cancer, the most aggressive type of breast cancer. In HIV, CytoDyn has successfully completed a Phase 3 pivotal trial with its investigational treatment in combination with standard anti-retroviral therapies. CytoDyn is also conducting a Phase 3 investigative trial for its targeted therapy as a once-weekly monotherapy for HIV. In autoimmune diseases, CytoDyn is conducting a Phase 2 trial for the prevention of graft-versus-host disease (GvHD) and is currently enrolling patients for a Phase 2 trial for the treatment of Nonalcoholic steatohepatitis (NASH).

To learn more about CytoDyn, visit http://www.cytodyn.com/

Contact:
Antonio Migliarese, Chief Financial Officer
360-980-8524
amigliarese@cytodyn.com
https://www.linkedin.com/in/antonio-migliarese-a2ba668/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved